A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV‐2 (COVID‐19) DHODH (dihydroorotate dehydrogenase) inhibitor

A therapeutic agent that targets both viral replication and the hyper‐reactive immune response would offer a highly desirable treatment for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; COVID‐19) management. Emvododstat (PTC299) was found to be a potent inhibitor of immunomodulatory a...

Descripción completa

Detalles Bibliográficos
Autores principales: Morton, Terri L., Laskin, Oscar L., Kaushik, Diksha, Lee, Lucy, Ma, Jiyuan, Kristensen, Allan, O'Keefe, Kylie, Golden, Lee, Klein, Matthew, Kong, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026081/
https://www.ncbi.nlm.nih.gov/pubmed/36938928
http://dx.doi.org/10.1002/prp2.1076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026081/
https://www.ncbi.nlm.nih.gov/pubmed/36938928
http://dx.doi.org/10.1002/prp2.1076

Ejemplares similares